CR8030A - TRANSDERMAL DOSE RESISTANT TO INTERFERENCES, INCLUDING AN ACTIVE AGENT COMPONENT AND AN HARMFUL AGENT COMPONENT ON THE DISTAL AGENT LAYER SITE - Google Patents

TRANSDERMAL DOSE RESISTANT TO INTERFERENCES, INCLUDING AN ACTIVE AGENT COMPONENT AND AN HARMFUL AGENT COMPONENT ON THE DISTAL AGENT LAYER SITE

Info

Publication number
CR8030A
CR8030A CR8030A CR8030A CR8030A CR 8030 A CR8030 A CR 8030A CR 8030 A CR8030 A CR 8030A CR 8030 A CR8030 A CR 8030A CR 8030 A CR8030 A CR 8030A
Authority
CR
Costa Rica
Prior art keywords
agent component
component
distal
interferences
active agent
Prior art date
Application number
CR8030A
Other languages
Spanish (es)
Inventor
A Howard Stephen
Reidenberg Bruce
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of CR8030A publication Critical patent/CR8030A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una forma de dosificacion transdermica que comprende un componente que contiene un agente activo que posee una superficie proxima y una superficie distal y un componente que contiene un agente adverso ubicado de manera distal al componente de agente activo en el que el componente de agente activo define al menos un canal que se extiende sustancialmente desde la superficie proxima a la superficie distal.The present invention relates to a transdermal dosage form comprising a component that contains an active agent that has a proximal surface and a distal surface and a component that contains an adverse agent located distally to the active agent component in which the Active agent component defines at least one channel that extends substantially from the surface proximal to the distal surface.

CR8030A 2003-04-30 2005-10-05 TRANSDERMAL DOSE RESISTANT TO INTERFERENCES, INCLUDING AN ACTIVE AGENT COMPONENT AND AN HARMFUL AGENT COMPONENT ON THE DISTAL AGENT LAYER SITE CR8030A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46723503P 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
CR8030A true CR8030A (en) 2007-10-22

Family

ID=36770597

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8030A CR8030A (en) 2003-04-30 2005-10-05 TRANSDERMAL DOSE RESISTANT TO INTERFERENCES, INCLUDING AN ACTIVE AGENT COMPONENT AND AN HARMFUL AGENT COMPONENT ON THE DISTAL AGENT LAYER SITE

Country Status (3)

Country Link
CN (1) CN1780611B (en)
CR (1) CR8030A (en)
ZA (1) ZA200507862B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102068697B (en) * 2010-12-30 2013-10-16 宜昌人福药业有限责任公司 Opiates painkiller and opiate receptor antagonist-containing medicinal composition
RU2700926C2 (en) * 2014-01-22 2019-09-24 4П Терапьютикс Transdermal systems preventing abuse and misuse
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
KR102279552B1 (en) * 2016-12-28 2021-07-19 히사미쓰 세이야꾸 가부시키가이샤 Patches containing butorphanol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form

Also Published As

Publication number Publication date
ZA200507862B (en) 2006-06-28
CN1780611B (en) 2013-01-30
CN1780611A (en) 2006-05-31

Similar Documents

Publication Publication Date Title
ECSP056191A (en) MANIFULATION RESISTANT TRANSDERMAL DOSAGE FORM INCLUDING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT ON THE DISTAL SURFACE OF THE LAYER OF THE ACTIVE AGENT
CY1121330T1 (en) COMPOSITIONS CONTAINING AZELASTIN AND METHODS OF USING THEM
ECSP088208A (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
CY1121593T1 (en) TETRAHYDROCANNAVINOL PRODUCTS, COMPOSITIONS INCLUDING TETRAHYDROCANNAVINOL PRODUCTS AND METHODS FOR USING THE SAME
SV2007002146A (en) DIFENYLIMIDAZOPIRIMIDINE AND IMIDAZOL AMINAS AS BETA-SECRETASA INHIBITORS REF. AM101727
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
ATE355065T1 (en) THERAPEUTIC COMPOSITIONS CONSISTING OF ANTIHYPOTENSIVES AND ANTIANGIOGENICS
AR055838A1 (en) FORMULATIONS FOR COVERED MICROPROJECTIONS THAT HAVE CONTROLLED SOLUBILITY
AR054227A1 (en) COMPOSITION OF ACTIVE PRINCIPLES
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
ATE540690T1 (en) INSULIN COMBINATIONS
SI1973539T1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
ECSP066878A (en) [HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - (4-BROMO-3-METHYL-5-PROPOXI-THIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE TRIPTASE
ES2250416T3 (en) STIMULANT OF SECRECIOHN OF HORMONE OF GROWTH.
MX2010005012A (en) Compositions for the treatment and prevention of eyelid swelling.
CL2007002875A1 (en) Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.
DK1680128T3 (en) Myo-inositol hexaphosphate for topical use
AR057876A1 (en) TREATMENT OF PATIENTS WITH CHRONIC RENAL DISEASE (ERC) USING COMPOUNDS OF THE INVENTION
CR8030A (en) TRANSDERMAL DOSE RESISTANT TO INTERFERENCES, INCLUDING AN ACTIVE AGENT COMPONENT AND AN HARMFUL AGENT COMPONENT ON THE DISTAL AGENT LAYER SITE
CY1114760T1 (en) Atherosclerosis Therapeutic Treatment
PA8651401A1 (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
AR026911A1 (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF TUMOR AFFECTIONS
PA8549401A1 (en) COMPLEX THAT INCLUDES INHIBITING FACTOR OF OSTEOCLASTOGENESIS AND POLISACARIDO
CL2004000767A1 (en) ORAL DOSING UNIT INCLUDING AN ANTAGONIST AGENT FOR PUMPS OF PROTONS AND EXCIPIENTS OF BASIC CHARACTER; PROCEDURE FOR PREPARATION, USEFUL TO TREAT DISEASES CAUSED BY AN INCREASED SECRETION OF GASTRIC ACIDS.